Active, not recruitingPHASE1, PHASE2NCT01687608
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Baxalta now part of Shire
- Principal Investigator
- Study DirectorShire
- Intervention
- AskBio009(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 18-75 years · MALE
- Timeline
- 2013 – 2030
Study locations (15)
- Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- University of California at San Diego Medical Center, San Diego, California, United States
- U of Colorado School of Medicine, Hemophilia & Thrombosis Treatment Center, Aurora, Colorado, United States
- Emory University, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Children's Hospital of Boston, Boston, Massachusetts, United States
- University of Minnesota, Masonic Clinical Research Unit, Clinical and Translational Science Institute, Minneapolis, Minnesota, United States
- Mount Sinai Medical Center, New York, New York, United States
- The Hemophilia Center, Oregon Health and Science University, Portland, Oregon, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Gulf States Hemophilia and Thrombosis Center, Houston, Texas, United States
- Bloodworks Northwest, Seattle, Washington, United States
- BloodCenter of Wisconsin, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01687608 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07285460A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BSanofi
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)CSL Behring
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China